Published February 12, 2020
| Version v1
Software
Open
Multi-Country Model Application for RSV Cost-Effectiveness Policy (McMarcel)
Authors/Creators
- 1. Centre for Health Economics Research & Modelling Infectious Diseases, Vaccine & Infectious Disease Institute, Universiteitsplein 1, University of Antwerp, Belgium
- 2. Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel Switzerland
- 3. Department of Infectious Disease Epidemiology, London school of Hygiene and Tropical Medicine, Keppel St, Bloomsbury, London, United Kingdom
Description
The objective of McMarcel is to evaluate the impact and cost-effectiveness of potential maternal and neonatal RSV immunisation strategies in 72 Gavi countries. The acronym stands for Multi-Country Model Application for RSV Cost-Effectiveness poLicy (McMarcel).
If you use parts of this modelling project, please cite: Li, Willem, Antillon, Bilcke, Jit, Beutels. Health and economic burden of Respiratory Syncytial Virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries. BMC Medicine. (2020) 18(1):82.